drugset / Trial / NCT05883644
Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)
NaSingle-groupOpen-labelTreatment
Summary
This study will assess the safety and efficacy of Single Tremelimumab Regular Interval Durvalumab (STRIDE) as first-line therapy in participants with advanced unresectable HCC.
Timeline
- Start
- 2023-06-27
- Primary completion
- 2026-03-30
- Completion
- 2026-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Participants will receive 1500 mg at Day 1 and later receive as monotherapy starting at Week 4 for every 4 weeks through IV infusion | Unknown | 1500 mg | Intravenous |
| Subject | Participants will receive single dose of 300 mg through IV infusion at Day 1 | Unknown | 300 mg | Intravenous |